Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid

Christopher W. Ryan, Dezheng Huo, Kathryn Bylow, Laurence M. Demers, Walter M. Stadler, Tara O. Henderson, Nicholas J. Vogelzang

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

OBJECTIVE: To report a randomized, placebo-controlled study of treatment with zoledronic acid every 3 months in patients with hormone-sensitive prostate cancer, both with and without bone metastases, to assess the effect on bone mineral density (BMD) and markers of bone turnover. PATIENTS AND METHODS: Eligible patients included those with prostate cancer and on androgen-deprivation therapy for <12 months. Patients received zoledronic acid 4 mg intravenously, or placebo, every 3 months for four treatments. BMD, urinary N-telopeptides of type I collagen (NTX), and serum bone alkaline phosphatase (BAP) were measured every 3 months. In all, 42 patients were randomized. RESULTS: After excluding BMD data from sites of known metastases, patients receiving zoledronic acid had a relative increase in BMD compared with those receiving placebo, of 4.2% and 7.1% at the femoral neck and lumbar spine, respectively. NTX and BAP decreased significantly in patients receiving zoledronic acid. NTX and BAP levels were significantly higher at baseline in patients with bone metastases than in those without. CONCLUSIONS: Treatment with zoledronic acid every 3 months preserved bone density and suppressed markers of bone turnover in patients with androgen-deprived prostate cancer, both with and without bone metastases.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalBJU International
Volume100
Issue number1
DOIs
StatePublished - Jul 1 2007

Fingerprint

zoledronic acid
Bone Remodeling
Bone Density
Prostatic Neoplasms
Hormones
Bone and Bones
Neoplasm Metastasis
Alkaline Phosphatase
Placebos
Androgens
Femur Neck
Therapeutics
Collagen Type I

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Ryan, Christopher W. ; Huo, Dezheng ; Bylow, Kathryn ; Demers, Laurence M. ; Stadler, Walter M. ; Henderson, Tara O. ; Vogelzang, Nicholas J. / Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. In: BJU International. 2007 ; Vol. 100, No. 1. pp. 70-75.
@article{68ebd744daf5464fa52cd8862155cde4,
title = "Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid",
abstract = "OBJECTIVE: To report a randomized, placebo-controlled study of treatment with zoledronic acid every 3 months in patients with hormone-sensitive prostate cancer, both with and without bone metastases, to assess the effect on bone mineral density (BMD) and markers of bone turnover. PATIENTS AND METHODS: Eligible patients included those with prostate cancer and on androgen-deprivation therapy for <12 months. Patients received zoledronic acid 4 mg intravenously, or placebo, every 3 months for four treatments. BMD, urinary N-telopeptides of type I collagen (NTX), and serum bone alkaline phosphatase (BAP) were measured every 3 months. In all, 42 patients were randomized. RESULTS: After excluding BMD data from sites of known metastases, patients receiving zoledronic acid had a relative increase in BMD compared with those receiving placebo, of 4.2{\%} and 7.1{\%} at the femoral neck and lumbar spine, respectively. NTX and BAP decreased significantly in patients receiving zoledronic acid. NTX and BAP levels were significantly higher at baseline in patients with bone metastases than in those without. CONCLUSIONS: Treatment with zoledronic acid every 3 months preserved bone density and suppressed markers of bone turnover in patients with androgen-deprived prostate cancer, both with and without bone metastases.",
author = "Ryan, {Christopher W.} and Dezheng Huo and Kathryn Bylow and Demers, {Laurence M.} and Stadler, {Walter M.} and Henderson, {Tara O.} and Vogelzang, {Nicholas J.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1111/j.1464-410X.2007.06853.x",
language = "English (US)",
volume = "100",
pages = "70--75",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. / Ryan, Christopher W.; Huo, Dezheng; Bylow, Kathryn; Demers, Laurence M.; Stadler, Walter M.; Henderson, Tara O.; Vogelzang, Nicholas J.

In: BJU International, Vol. 100, No. 1, 01.07.2007, p. 70-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid

AU - Ryan, Christopher W.

AU - Huo, Dezheng

AU - Bylow, Kathryn

AU - Demers, Laurence M.

AU - Stadler, Walter M.

AU - Henderson, Tara O.

AU - Vogelzang, Nicholas J.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - OBJECTIVE: To report a randomized, placebo-controlled study of treatment with zoledronic acid every 3 months in patients with hormone-sensitive prostate cancer, both with and without bone metastases, to assess the effect on bone mineral density (BMD) and markers of bone turnover. PATIENTS AND METHODS: Eligible patients included those with prostate cancer and on androgen-deprivation therapy for <12 months. Patients received zoledronic acid 4 mg intravenously, or placebo, every 3 months for four treatments. BMD, urinary N-telopeptides of type I collagen (NTX), and serum bone alkaline phosphatase (BAP) were measured every 3 months. In all, 42 patients were randomized. RESULTS: After excluding BMD data from sites of known metastases, patients receiving zoledronic acid had a relative increase in BMD compared with those receiving placebo, of 4.2% and 7.1% at the femoral neck and lumbar spine, respectively. NTX and BAP decreased significantly in patients receiving zoledronic acid. NTX and BAP levels were significantly higher at baseline in patients with bone metastases than in those without. CONCLUSIONS: Treatment with zoledronic acid every 3 months preserved bone density and suppressed markers of bone turnover in patients with androgen-deprived prostate cancer, both with and without bone metastases.

AB - OBJECTIVE: To report a randomized, placebo-controlled study of treatment with zoledronic acid every 3 months in patients with hormone-sensitive prostate cancer, both with and without bone metastases, to assess the effect on bone mineral density (BMD) and markers of bone turnover. PATIENTS AND METHODS: Eligible patients included those with prostate cancer and on androgen-deprivation therapy for <12 months. Patients received zoledronic acid 4 mg intravenously, or placebo, every 3 months for four treatments. BMD, urinary N-telopeptides of type I collagen (NTX), and serum bone alkaline phosphatase (BAP) were measured every 3 months. In all, 42 patients were randomized. RESULTS: After excluding BMD data from sites of known metastases, patients receiving zoledronic acid had a relative increase in BMD compared with those receiving placebo, of 4.2% and 7.1% at the femoral neck and lumbar spine, respectively. NTX and BAP decreased significantly in patients receiving zoledronic acid. NTX and BAP levels were significantly higher at baseline in patients with bone metastases than in those without. CONCLUSIONS: Treatment with zoledronic acid every 3 months preserved bone density and suppressed markers of bone turnover in patients with androgen-deprived prostate cancer, both with and without bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=34249950226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249950226&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.06853.x

DO - 10.1111/j.1464-410X.2007.06853.x

M3 - Article

C2 - 17552955

AN - SCOPUS:34249950226

VL - 100

SP - 70

EP - 75

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -